Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

Nicolo' Gebbia, Antonio Russo, Marianna Silletta, Di Cuonzo, Laura Rocci, Fabrizio Battistoni, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Michele Gavasci

Risultato della ricerca: Articlepeer review

25 Citazioni (Scopus)


Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of humanneoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatmentfailure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of thevascular endothelial growth factor (VEGF) and interferon-c (IFN-c) in advanced colorectal cancer patients duringtreatment with a weekly combination of cetuximab plus irinotecan.Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated forcirculating levels of VEGF and IFN-c during the treatment with cetuximab (initial dose of 400 mg/m2, followed byweekly infusions of 250 mg/m2) plus weekly irinotecan (90 mg/m2). The circulating levels of the cytokines wereassessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plusirinotecan treatment.Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatmentinfusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance92 days after the first infusion (P < 0.0001). On the contrary, IFN-c values showed a statistical significant increase oneday after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was nomore evident at the following time points. Moreover, a linear regression model with variance analysis showeda significant negative correlation between VEGF and IFN-c values 1, 21 and 50 days after the treatment beginning(P = 0.002, 0.001 and 0.047, respectively).Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels.The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study weidentified a IFN-c increase, even if the specific role of this behavior remains to be investigated.
Lingua originaleEnglish
pagine (da-a)835-841
Numero di pagine7
RivistaAnnals of Oncology
Stato di pubblicazionePublished - 2006

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???


Entra nei temi di ricerca di 'Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.'. Insieme formano una fingerprint unica.

Cita questo